TY  - CHAP
M1  - Book, Section
TI  - Adjuvant and Neoadjuvant Chemotherapy
A1  - Owen, Dwight H.
A1  - Chaft, Jamie E.
A2  - Sugarbaker, David J.
A2  - Bueno, Raphael
A2  - Burt, Bryan M.
A2  - Groth, Shawn S.
A2  - Loor, Gabriel
A2  - Wolf, Andrea S.
A2  - Williams, Marcia
A2  - Adams, Ann
PY  - 2020
T2  - Sugarbaker’s Adult Chest Surgery, 3e
AB  - The  only  curative  intervention  for  early-stage  (I-IIIA)  non–small-cell  lung  cancer  (NSCLC)  is  surgical  resection.  Yet,  despite  optimal  surgical  care,  the  chance  of  recurrence  and  death  due  to  NSCLC  is  high.1,2  Adjuvant  (postoperative)  and  neoadjuvant  (preoperative)  treatment  with  chemotherapy  has  prolonged  survival  in  select  patients  with  early-stage  NSCLC  in  both  prospective  trials  and  systemic  meta-analyses.  This  chapter  summarizes  the  evidence  supporting  the  use  of  adjuvant  and  neoadjuvant  therapy  for  patients  with  early-stage  NSCLC.  It  also  highlights  the  areas  where  more  research  is  needed  and  explores  ongoing  research  strategies  to  optimize  both  patient  and  treatment  selection  to  achieve  the  best  outcome  for  this  patient  population.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/18
UR  - accesssurgery.mhmedical.com/content.aspx?aid=1170411526
ER  -